HONG KONG – China's I-Mab Biopharma Co. Ltd. entered a strategic partnering agreement with ABL Bio Inc., of South Korea. I-Mab will out-license its bispecific antibody (BsAb) for an undisclosed target to ABL Bio for about $100 million.
HONG KONG – Singaporean biotech startup Dotbio Pte. Ltd. launched this week with seed capital of $2.3 million. The new player on the biotech scene is focused on the development of immuno-oncology drugs based on humanized domain antibodies.
HONG KONG –MSD China Holding Co. Ltd. (known as Merck & Co. Inc. in the U.S. and Canada) received approval for Keytruda (pembrolizumab) in China, making it the second PD-1 inhibitor drug approved in the country after Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and the first one for advanced melanoma.
HONG KONG –MSD China Holding Co. Ltd. (known as Merck & Co. Inc. in the U.S. and Canada) received approval for Keytruda (pembrolizumab) in China, making it the second PD-1 inhibitor drug approved in the country after Bristol-Myers Squibb Co.'s Opdivo (nivolumab) and the first one for advanced melanoma.
HONG KONG – Astrazeneca plc has won two new approvals from Japan's PMDA for its Lynparza (olaparib) in breast cancer as well as chemotherapy maintenance drug Imfinzi (durvalumab), a further sign that the country is getting faster in approving these drugs, reflecting an urgency in accessing newer cancer treatments.
HONG KONG – Compugen Inc. has two investigational new drug applications (INDs) recently approved by the FDA, as the Israeli company is set to transform from a predictive drug discovery and development company into a clinical-stage venture.
HONG KONG – Compugen Inc. has two investigational new drug applications (INDs) recently approved by the FDA, as the Israeli company is set to transform from a predictive drug discovery and development company into a clinical-stage venture.
